Sravnitel'noe issledovanie vliyaniya antidepressivnoy terapii na kognitivnye narusheniya u bol'nykh nepsikhoticheskimi depressivnymi rasstroystvami


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The analysis of the results of prospective non-randomized clinical trial of the influence of antidepressants and their combination with nootropics and cognitive-behavioral therapy on cognitive impairment in patients with non-psychotic depressive disorders was performed. In patients with depressive disorders, the lower parameters of short-term memory, neurodynamic activity, regulatory (executive) functions, stress resistance and strength of the nervous processes in comparison with the average values in population were identified. Application of thymoanaleptics did not have a positive impact on short-term memory, improving neurodynamic performance in general. At the same time, tricyclic antidepressants had negative impact on attention. Improvement of short term memory occurred only in case of use of nootropic drugs in addition to the therapy. Combined use of antidepressants and cognitive-behavioral therapy increased the positive impact on many parameters of cognitive functioning.

Full Text

Restricted Access

References

  1. Аведисова А.С. Особенности психофармакотерапии больных с пограничными психическими расстройствами (клиникофармакологическое изучение действия антидепрессантов, ноотропов и гипнотиков). Дисс. д.м.н. М., 1999.
  2. Аведисова A.C., Ахапкин Р.В., Ахапкина В.И., Вериго Н.Н. Пирацетам в свете современных исследований (анализ зарубежных исследований). Психиатрия и психофармакотерапия. 2000; 6: 178-84.
  3. Аведисова A.C., Спасова С.А. Влияние антидепрессантов на интеллектуально-мнестические функции как отражение их поведенческой токсичности. Социальная и клиническая психиатрия. 2000; 10(2): 30-4.
  4. Александровский Ю.А. Пограничные психические расстройства. М., 2000. 301 с.
  5. Мосолов С.Н. Клиническое применение современных антидепрессантов. СПб., 1995. 568 с.
  6. Воронина Т.А. Экспериментальная психофармакология ноотропов (экспериментальное и клиническое изучение). М., 1989. С. 8-19.
  7. Austin M.P., Mitchell P., Goodwin G.M. Cognitive deficits in depression: possible implica -tions for functional neuropathology. The British Journal of Psychiatry. 2001; 178: 200-06.
  8. Baune B.T., Miller R., McAfoose J., Johnson M.,
  9. Beblo T., Sinnamon G., Baune B.T. Specifying the neuropsychology of affective disorders: clinical, demographic and neurobiological factors. Neuropsychology Review. 2011; 21: 337-59.
  10. Deckersbach T., Ottowitz W.E., Savage C.R., Lindquist M.A., Dougherty D.D. Neural correlates of strategic processes underlying episodic memory in women with major depression: A 15O-PET study. J. Neuropsychiatry Clin. Neurosci. 2010; 22(2): 218-30.
  11. Den Hartog H.M., Derix M.M., Van Bemmel A.L., Kremer B., Jolles J. Cognitive functioning in young and middle-aged unmedicated outpatients with major depression: testing the effort and cognitive speed hypotheses. Psychol. Med. 2003; 33(8): 1443-51.
  12. Goldstein B.J., Goodnick P.J. Selective serotonin reuptake inhibitors in the treatment of affective disorders-III. Tolerability, safety and pharmacoeconomics. J. Psychopharmacol. 1998; 12(3 Suppl. B): 55-87.
  13. Herrara-Guzman I.,Gudayol-Ferre E.,Herrera-Guzman D., Guardia-Olmos J., Hinojosa-Calvo E., Herrera-Abarca J.E. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J. Psychiatric. Res. 2009; 43: 855-63.
  14. Hyttel J. Pharmacological characterisation of selective serotonin reuptake inhibitors (SSRI). Int. Clin. Psychopharm. 1994; 9(Suppl. 1): 19-26.
  15. Lee R.S.C., Hermens D.F., Porter M.A., Redoblado-Hodge M.A. A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder. Journal of Affective Disorders. 2012; 140: 113-24.
  16. Marazziti D., Consoli G., Picchetti M., Carlini M., Faravelli L. Cognitive impairment in major depression. Eur. J. Pharmacol. 2010; 626(1): 83-6.
  17. McCabe C., Mishor Z., Cowen P.J., Harmer C.J. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biolog. Psychiatr. 2010; 67: 439-45.
  18. McCabe C., Mishor Z. Antidepressant medications reduce subcortical cortical resting-state functional connectivity in healthy volunteers. Neuroimage. 2011; 57: 1317-23.
  19. McClintock S.M., Husain M., Greer T.L., Cullum C.M. Association between depression severity and neurocognitive function in major depressive disorder. Neuropsychology. 2010; 24: 9-34.
  20. McIntyre R.S., Cha D.S., Soczynska J.K., Woldeyohannes H.O., Gallaugher L.A., Kudlow P., Alsuwaidan M., Baskaran A. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depression and Anxiety. 2013; 30: 515-27.
  21. Montgomery S.A. Selecting the optimum therapeutic dose with citalopram of serotonin reuptake inhibitors: study. Int. Clin. Psychopharm. 1995; 10(Suppl. 1): 23-7.
  22. Porter R.J., Bourke C., Gallagher P. Neuropsychological impairment in major depression: its nature, origin and clinical significance. Aust. N. Z. J. Psychiatry. 2007; 41: 115-28.
  23. Rihmer Z. Angst J. Mood disorders: epidemiology. In: Kaplan and Sadock's Comprehensive Textbook of Psychiatry. Sadock B.J. and Sadock V.A., eds. 8th edn. Wotlters Kluwer; Lippincott Williams & Wilkins, 2005. P. 1575-82.
  24. Timmerman L., Haffmans P.M.J., Hoogdin C.A.L. Citalopram in major depression: a comparative study with fluvoxamine, preliminary results. In: Past. Present and future of psychiatry. 1993.
  25. Trivedi M.H., Rush A.J., Wisniewski S.R., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry. 2006; 163. 28-40.
  26. Wittchen H.U., Jacobi F., Rehm J., Gustavsson A., Svensson M., Jönsson B., Olesen J., Allgulander C., Alonso J., Faravelli C., Fratiglioni L., Jennum P., Lieb R., Maercker A., van Os J., Preisig M., Salvador-Carulla L., Simon R., Steinhausen H.C. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 2011; 21(9): 655-79.
  27. Zakzanis K.K., Leach L., Kaplan E. On the nature and pattern of neurocognitive function in major depressive disorder. Neuropsychiatry Neuropsychol. Behav. Neurol. 1998; 11: 111-19.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies